ATRA — ATARA BIOTHERAPEUTICS INC
Public company
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
About ATARA BIOTHERAPEUTICS INC (ATRA)
ATARA BIOTHERAPEUTICS INC (ATRA) appears in the most recent 13F filings of 3 tracked institutional investors. The largest disclosed position is held by Steve Cohen (Point72 Asset Management), valued at $918,869. Across recent filings, tracked investors recorded 3 new positions, 0 increased, 0 reduced, and 0 exited. All data sourced from SEC 13F filings.
Based on recent institutional activity in ATRA
How many top investors track ATRA
A small number of top investors own this.
ATRA Ownership Composition
How ATARA BIOTHERAPEUTICS INC is held across tracked investor types, based on reported 13F positions.
- Hedge Funds64.4%
- Other35.6%
Tracked investors reporting ATRA
- Steve CohenMar 31, 2026Point72 Asset ManagementShares194.3KValue$918.9K% Portfolio0.00%
- Ken GriffinDec 31, 2025Citadel AdvisorsShares15.6KValue$281.8K% Portfolio0.00%
- Izzy EnglanderMar 31, 2026Millennium ManagementShares47.7KValue$225.6K% Portfolio0.00%
Recent activity
- $225.6KMay 15, 2026
- New$331KFeb 17, 2026
- New$918.9KMay 15, 2026
Frequently asked questions
- How many institutional investors hold ATRA?
- 3 tracked institutional investors disclosed a position in ATRA (ATARA BIOTHERAPEUTICS INC) in their most recent 13F filing.
- Who is the largest institutional holder of ATRA?
- Steve Cohen, Point72 Asset Management, holds the largest disclosed position in ATRA, valued at $918,869.
- Did institutional ownership of ATRA increase or decrease?
- Across recent 13F filings, tracked investors recorded 3 new positions, 0 increased, 0 reduced, and 0 fully exited ATRA.
- Where does this ATRA ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.